Long-term remission of leukemia after failure of cord blood stem cell transplantation for high-risk childhood acute lymphoblastic leukemia: a report of one case and literature review
-
摘要:
目的 分析儿童高危急性淋巴细胞白血病脐血移植失败后白血病长期缓解的原因。 方法 收集2013年9月在中山大学附属第三医院血液内科接受脐血干细胞移植的1例高危急性淋巴细胞白血病患儿的临床资料。分析患儿术后治疗过程及预后, 并结合文献资料分析患者移植失败但白血病治疗获得良好效果的可能原因。 结果 患儿首次脐血干细胞移植后造血恢复不良, 2013年11月行脐血输注, 后因为经济原因未针对原发病进一步治疗, 然而该患者脐血移植术后15个月造血功能恢复, 至2015年9月, 脐血移植后2年无病生存。 结论 脐血移植或输注可能具有修复造血及免疫系统的功能, 且无需通过成功植入发挥作用。儿童高危白血病进行脐血移植植入失败并不意味白血病治疗失败, 患儿有可能获得长期无病生存。 Abstract:Objective To analyze the reasons for long-term remission of leukemia after failure of cord blood stem cell transplantation for high-risk childhood acute lymphoblastic leukemia. Methods Clinical data of 1 child with high-risk acute lymphoblastic leukemia undergoing cord blood stem cell transplantation in the Department of Hematology of the Third Affiliated Hospital of Sun Yat-sen University in September 2013 were collected. The treatment course and prognosis of the child were analyzed. In combination with literatures, the possible reasons for the good treatment effect on leukemia after transplantation failure were analyzed. Results The hematopoietic recovery of the child after the first cord blood stem cell transplantation was poor. The child underwent cord blood infusion in November 2013 and did not undergo further treatment for the primary disease due to economic reasons. However, the hematopoietic function recovered 15 months after cord blood transplantation. Till September 2015, 2-year disease free survival after cord blood transplantation was obtained. Conclusions Cord blood transplantation or infusion may repair the function of hematopoietic system and immune system, and may take effect with no need of successful transplantation. The failure of cord blood transplantation for childhood high-risk leukemia does not mean treatment failure. Children patients may obtain long-term disease free survival. -
Key words:
- Leukemia, acute /
- Child /
- High-risk /
- Cord blood transplantation /
- Transplantation failure /
- Cord blood infusion
-
表 1 本例受者与供者的脐血HLA分型结果
Table 1. The human leukocyte antigen matching of this recipient and his donor
受者及供者 HLA-A HLA-B HLA-Cw HLA-DRB1 HLA-DQB1 受者(患儿) 0301/1101 3501/5101 0401/1402 0101/1405 0501/0503 供者 脐血移植(2013-09-09) 0301/1101 4001/5101 0702/1502 0101/1405 0501/0503 脐血输注(2013-11-04) 11/74 35/51 01/14 注：脐血移植时，HLA配型为低分辨5/6相合，高分辨7/10相合；脐血输注时，HLA配型为低分辨5/6相合 
下载: 导出CSV
-
[1] Politikos I, Boussiotis VA. The role of the thymus in T-cell immune reconstitution after umbilical cord blood transplantation[J]. Blood, 2014, 124(22):3201-3211. doi: 10.1182/blood-2014-07-589176 [2] Zheng C, Tang B, Tong J, et al. Unrelated cord blood transplantation for central nervous system relapse in high-risk childhood acute lymphoblastic leukemia[J]. Ann Hematol, 2013, 92(12):1665-1673. doi: 10.1007/s00277-013-1820-3 [3] Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia[J]. J Clin Oncol, 1996, 14(1):18-24. http://cn.bing.com/academic/profile?id=2119685895&encoded=0&v=paper_preview&mkt=zh-cn [4] Moricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival:treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95[J]. Blood, 2008, 111(9):4477-4489. doi: 10.1182/blood-2007-09-112920 [5] Parma M, Vigano C, Fumagalli M, et al. Good outcome for very high risk adult b-cell acute lymphoblastic leukaemia carrying genetic abnormalities t(4;11)(q21;q23) or t(9;22)(q34;q11), if promptly submitted to allogeneic transplantation, after obtaining a good molecular remission[J]. Mediterr J Hematol Infect Dis, 2015, 7(1):e2015041. doi: 10.4084/mjhid.2015.041 [6] Pulsipher MA, Peters C, Pui CH. High-risk pediatric acute lymphoblastic leukemia:to transplant or not to transplant?[J]. Biol Blood Marrow Transplant, 2011, 17(1 Suppl):S137-S148. http://cn.bing.com/academic/profile?id=2079459221&encoded=0&v=paper_preview&mkt=zh-cn [7] Arico M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia[J]. N Engl J Med, 2000, 342(14):998-1006. doi: 10.1056/NEJM200004063421402 [8] 阮永胜, 吴学东, 冯晓勤, 等. ALL-BFM95方案治疗儿童急性淋巴细胞白血病高危患儿的预后分析[J].中国当代儿科杂志, 2015, 17(4):327-331. http://www.cnki.com.cn/article/cjfdtotal-ddkz201504007.htmRuan YS, Wu XD, Feng XQ, et al. Outcome of childhood high-risk acute lymphoblastic leukemia treated with the ALLBFM 95 protocol[J]. Chin J Contemp Pediatr, 2015, 17(4):327-331. http://www.cnki.com.cn/article/cjfdtotal-ddkz201504007.htm [9] 罗学群, 柯志勇, 黄礼彬, 等.儿童高危和超高危急性淋巴细胞白血病的预后因素分析[J].中山大学学报:医学科学版, 2008, 29(6):767-771, 776. http://www.cnki.com.cn/Article/CJFDTOTAL-ZSYK200806031.htmXue Q, Ke ZY, Huang LB, et al. Analysis of prognostic factors of high-risk and very high-risk childhood acute lymphoblastic leukemia[J]. J Sun Yat-sen Univ:Med Sci, 2008, 29(6):767-771, 776. http://www.cnki.com.cn/Article/CJFDTOTAL-ZSYK200806031.htm [10] Zhang H, Chen J, Que W. A meta-analysis of unrelated donor umbilical cord blood transplantation versus unrelated donor bone marrow transplantation in acute leukemia patients[J]. Biol Blood Marrow Transplant, 2012, 18(8):1164-1173. doi: 10.1016/j.bbmt.2012.01.015 [11] Sun ZM. Advance in umbilical cord blood hematopoietic stem cell transplantation[J]. Chin J Pract Int Med, 2014, 34(2):127-131. http://en.cnki.com.cn/Article_en/CJFDTotal-SYNK201402009.htm [12] Eapen M, Klein JP, Sanz GF, et al. Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome:a retrospective analysis[J]. Lancet Oncol, 2011, 12(13):1214-1221. doi: 10.1016/S1470-2045(11)70260-1 [13] Munoz J, Shah N, Rezvani K, et al. Concise review:umbilical cord blood transplantation:past, present, and future[J]. Stem Cells Transl Med, 2014, 3(12):1435-1443. doi: 10.5966/sctm.2014-0151 [14] Yao Y, Song Q, Chu Y, et al. Infusion of allogeneic umbilical cord blood hematopoietic stem cells in patients with chemotherapy-related myelosuppression[J]. Exp Ther Med, 2014, 8(6):1946-1950. http://cn.bing.com/academic/profile?id=2092534475&encoded=0&v=paper_preview&mkt=zh-cn [15] 肖佩芳, 胡绍燕, 何海龙, 等.异基因造血干细胞移植治疗儿童重型再生障碍性贫血疗效分析[J].中国实验血液学杂志, 2015, 23(4):1103-1107. http://www.cnki.com.cn/article/cjfdtotal-xysy201504044.htmXiao PF, Hu SY, He HL, et al. Efficacy analysis of allogeneic hematopoietic stem cell transplantation for children with severe aplastic anemia[J]. Chin J Exp Hematol, 2015, 23(4):1103-1107. http://www.cnki.com.cn/article/cjfdtotal-xysy201504044.htm [16] Liu HL, Sun ZM, Geng LQ, et al. Unrelated cord blood transplantation for newly diagnosed patients with severe acquired aplastic anemia using a reduced-intensity conditioning:high graft rejection, but good survival[J]. Bone Marrow Transplant, 2012, 47(9):1186-1190. doi: 10.1038/bmt.2011.251 [17] Zhou F, Ge L, Yu Z, et al. Clinical observations on intensive immunosuppressive therapy combined with umbilical cord blood support for the treatment of severe aplastic anemia[J]. J Hematol Oncol, 2011, 4:27. doi: 10.1186/1756-8722-4-27 [18] Carrancio S, Blanco B, Romo C, et al. Bone marrow mesenchymal stem cells for improving hematopoietic function:an in vitro and in vivo model. part 2:effect on bone marrow microenvironment[J]. PLoS One, 2011, 6(10):e26241. doi: 10.1371/journal.pone.0026241 [19] Castro-Manrreza ME, Montesinos JJ. Immunoregulation by mesenchymal stem cells:biological aspects and clinical applications[J]. J Immunol Res, 2015:394917. http://cn.bing.com/academic/profile?id=1982254468&encoded=0&v=paper_preview&mkt=zh-cn -
下载: 
点击查看大图
表(1)
计量
- 文章访问数: 138
- HTML全文浏览量: 94
- PDF下载量: 4
- 被引次数: 0
